WO2012014165A1 - A method of managing broncho-constrictive condition - Google Patents
A method of managing broncho-constrictive condition Download PDFInfo
- Publication number
- WO2012014165A1 WO2012014165A1 PCT/IB2011/053345 IB2011053345W WO2012014165A1 WO 2012014165 A1 WO2012014165 A1 WO 2012014165A1 IB 2011053345 W IB2011053345 W IB 2011053345W WO 2012014165 A1 WO2012014165 A1 WO 2012014165A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agents
- procyanidin
- composition
- concentration ranging
- broncho
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Definitions
- the present disclosure is related to management of broncho-constrictive conditions like Allergic Rhinitis, Asthma, and Chronic obstructive pulmonary disease (COPD).
- the broncho-constrictive condition is managed by administering a composition comprising pentameric type A procyanidin, trimeric procyanidin and tetrameric procyanidin, optionally along with pharmaceutical excipient(s).
- Catechins are polyphenolic plant metabolites which belong to the flavonoid family. The molecular formula and weight of catechins are C15H14O6 and 290 g/mol. Catechin and epicatechin are epimers, with (-)-epicatechin and (+)-catechin being the most common optical isomers found in nature. Procyanidins or condensed tannins are flavonoid oligomers whose building blocks are (+) - catechin and (-) - epicatechin. They are present abundantly in the plant kingdom in fruits, barks, leaves and seeds where they provide protection against light, oxidation and predators. Procyanidins are found in many plants, mainly apples, pine bark, cinnamon bark, litchi pericarp, peanuts, grape seed, cocoa, grape skin, bilberry, cranberry, black currant, green tea and black tea.
- procyanidins Based on the linkage between the successive monomeric units, procyanidins are classified as Types A, B or C polyphenols. Generally the linkage between successive monomeric units of procyanidins is between the 4 th position of the 'upper' unit and the 8 th position of the 'lower' unit, leading to a Type B procyanidin. Alternatively, the linkage can occur between C 4 of the 'upper' unit and C 6 of the lower unit, leading to a Type C procyanidin. Type B and C polyphenols are abundantly seen in many botanical sources.
- Broncho-constrictive conditions are characterized by symptoms of significantly reduced ability to breathe along with coughing and wheezing. This condition produces adverse impact on the airways or bronchioles, which carry air between the bronchi and the alveoli. Inflammation of the bronchioles and clamping of the smooth muscle outside of the bronchioles cause reduced passage of air in or out of the lungs.
- Allergic Rhinitis is the most common chronic respiratory illness. It affects quality of life, productivity and is associated with co-morbid conditions such as Asthma. Symptoms of Allergic Rhinitis include rhinorrhea, nasal congestion, obstruction, and pruritus which are triggered by contact with allergens like bacteria, viruses, animal parasites, dust, pollen, chemicals, food, drugs, smoke etc. Asthma is a similar chronic broncho-constrictive condition with airway restriction, mucus production and allergic reaction.
- COPD chronic obstructive pulmonary disease
- bronchodilators to open the airways, such as ipratropium, tiotropium, salmeterol, or formoterol; and inhaled steroids to reduce lung inflammation.
- Bhaskaran et al. discloses a composition comprising pentameric procyanidin flavonoid of concentration ranging from about 55% w/w to about 99% w/w, trimers and tetramers each at a concentration ranging from about 0.5%) w/w to about 35% w/w.
- This document also discloses a process for preparation of the said composition from plant sources namely Cinnamon, Litchi and Arachis. Further, this document teaches use of the said composition for treatment and management of HIV infection, AIDS and Influenza virus infection. However, this document does not suggest or teach the use of the said composition in treatment, prevention and management of broncho-constrictive conditions.
- WO2007053641 A2 teaches that A-type procyanidins inhibit COX-2 gene transcription in a cell line. Based on this cell line experiment it extrapolates and speculates potential anti-inflammatory action in in- vivo conditions.
- this document does not motivate or demonstrate the action of A-type procyanidins in treating, preventing and managing broncho-constrictive conditions namely allergic rhinitis, asthma and COPD.
- Inhibition of COX-2 enzyme synthesis as discussed by this document has no implication on secretion of leukotrienes.
- Leukotrienes are the mediators involved in inflammation of the bronchiols or the airway in broncho- constrictive conditions namely allergic rhinitis, asthma and COPD.
- COX-2 inhibition can have adverse effect in broncho-constrictive conditions since it inhibits secretion of prostaglandin E2 (PGE2).
- PGE2 has bronchoprotective effect in asthma and other pulmonary conditions.
- aspirin-induced asthma may be triggered by increased release of leukotrienes from inflammatory cells caused by removal of the inhibitory influence of PGE2, a major product of COX-2 in airways.
- PGE2 has pronounced adverse cardiovascular side effects which lead to withdrawal best selling approved COX-2 inhibitor drugs like Vioxx from the market.
- WO2007053641 A2 does not motivate or teach a person skilled in the art to investigate A-type procyanidins for treating, preventing and managing broncho-constrictive conditions namely allergic rhinitis, asthma and COPD.
- the present disclosure relates to a method of managing broncho- constrictive condition, said method comprising act of administering a composition comprising pentameric type A procyanidin, trimeric procyanidin and tetrameric procyanidin, optionally along with one or more pharmaceutical excipient, to subject in need thereof.
- the present disclosure relates to a method of managing broncho-constrictive condition, said method comprising act of administering a composition comprising pentameric type A procyanidin, trimeric procyanidin and tetrameric procyanidin, optionally along with one or more pharmaceutical excipient, to subject in need thereof.
- the broncho-constrictive condition is selected from group comprising allergic rhinitis, asthma and chronic obstructive pulmonary disease or any combinations thereof.
- the pentameric type A procyanidin is at concentration ranging from about 55 % w/w to about 99% w/w
- the trimeric procyanidin and the tetrameric procyanidin are each at concentration ranging from about 0.5 % w/w to about 35 % w/w
- the pharmaceutical excipient is at concentration ranging from about 0.5 % to about 99.9 %.
- the pentameric type A procyanidin is at concentration ranging from about 80 % w/w to about 90% w/w
- the trimeric procyanidin and the tetrameric procyanidin are each at concentration ranging from about 0.5 % w/w to about 20 % w/w.
- the pharmaceutical excipient is selected from group comprising gums, granulating agents, binders, lubricants, disintegrating agents, sweetening agents, additives, solvents, glidants, anti-adherents, anti-static agents, surfactants, anti-oxidants, surfactants, viscocity enhancers, plant cellulosic material coloring agents, flavoring agents, coating agents, plasticizers, preservatives, suspending agents, emulsifying agents, antistatic agents and spheronization agents or any combinations thereof.
- the composition is formulated into dosage forms selected from group comprising tablet, troches, lozenges, aqueous or oily suspensions, ointment, patch, gel, lotion, dentifrice, capsule, emulsion, creams, spray, drops, dispersible powders or granules, emulsion in hard or soft gel capsules, syrups, elixirs, nasal spray, inhalers, nebulizers, intravenous injection, intravenous solutions, intramuscular injections, intramuscular depot, subcutaneous injection, percutaneous injection, phytoceuticals, nutraceuticals and food stuffs or any combinations thereof.
- the composition is administered at dose ranging from about 1 mg/kg to about 100 mg/kg body weight of the subject. In still another embodiment of the present disclosure, the composition is administered as a spray at dose ranging from about 1 ⁇ g/kg to about 25 ⁇ g/kg body weight of the subject.
- the subject is a mammal, including but not limiting to human beings.
- the term managing or management includes preventing and treating of a disease condition or disorder or ill effects or side effects.
- the term also encompasses maintenance of the optimum state and prevention of the further progress in the disease condition or disorder or ill effects or side effects.
- the present disclosure relates to a method of managing broncho-constrictive conditions in a subject in need thereof, wherein said method comprises step of administering pharmaceutically effective amount of a composition comprising pentameric type-A procyanidin, trimers and tetramers of procyanidin, optionally along with pharmaceutically acceptable excipient(s).
- the concentration of pentameric procyanidin flavonoid is ranging from about 80 % w/w to about 99 % w/w, trimers and tetramers of procyanidin flavonoid each at concentration ranging from about 0.5 % w/w to about 20 % w/w.
- said excipient is selected from a group comprising gums, granulating agents, binders, lubricants, disintegrating agents, sweetening agents, additives, solvents, glidants, anti-adherents, anti-static agents, surfactants, anti-oxidants, surfactants, viscocity enhancers, plant cellulosic material coloring agents, flavoring agents, coating agents, plasticizers, preservatives, suspending agents, emulsifying agents, antistatic agents, and spheronization agents or any combination thereof.
- said composition is formulated into various dosage forms selected from a group comprising tablet, troches, lozenges, aqueous or oily suspensions, liquid, ointment, patch, gel, lotion, dentifrice, capsule, emulsion, creams, spray, drops, dispersible powders or granules, emulsion in hard or soft gel capsules, syrups, elixirs, nasal spray, inhalers, nebulizers, intravenous injection, Intravenous solutions, Intramuscular injections, Intramuscular depot, subcutaneous injection, percutaneous injection, phytoceuticals, nutraceuticals and food stuffs or any combination thereof.
- composition is used for the prevention, treatment and management of broncho-constrictive conditions like Allergic Rhinitis, Asthma, and Chronic obstructive pulmonary disease (COPD).
- broncho-constrictive conditions like Allergic Rhinitis, Asthma, and Chronic obstructive pulmonary disease (COPD).
- COPD Chronic obstructive pulmonary disease
- the activity can be treatment, management or preventive in nature.
- the monomeric unit of the composition is chosen from a group of catechins, preferable catechin or epicatechin.
- this composition is administered to animals and human beings.
- the Pharmacokinetic parameters of the instant composition is studied in healthy rats to determine the bioavailability of the instant composition.
- Male Swiss Wistar rats weighing about 150-200 gm are orally administered a single dose of present composition at about 100 mg/kg of body weight.
- Blood is withdrawn by retro orbital puncture at 0, 5, 15, 30, 60, 90, 120, 150, 180 minutes.
- Plasma is obtained by centrifugation of blood at about 10000 rpm at about 4°C for about 20 min.
- Reverse Phase HPLC method described below has been developed for detection of the instant composition in the plasma.
- Injection volume about 20 ⁇
- UV Detection Wavelength about 280 nm
- the present composition showed a plasma half life (Ti /2 ) of about 4 hrs and maximum plasma concentration (C max ) of about 109.213 ⁇ g/ ml.
- Prophylactic activity of instant composition against antigen-induced broncho- constriction is tested in sensitized guinea pigs.
- Male Duncan Hartley derived guinea pigs 400 ⁇ 50 g are pretreated with instant composition at dose of about 100 mg/kg of body weight of the subject, administered orally.
- the guinea pigs are sensitized with intraperitoneal injection of ovalbumin (0.5 ⁇ g).
- a cocktail of Indomethacin (about 10 mg/kg), Mepyramine (about 2mg/kg) and Propanolol (about 100 mg/kg) is injected about 10 mins before sensitization in order to block other mediators of broncho-blockade.
- Sensitized animals are anesthetized and artificially ventilated.
- n 5; Data Analyzed using One-way ANOVA followed by Dunnett's Multiple Comparison test; P ⁇ 0.05 as compared to Vehicle Control group.
- the instant composition comprising type A pentameric procyanidin flavonoid of concentration ranging from about 55 % w/w to about 99% w/w, trimers and tetramers of procyanidin flavonoid each at concentration ranging from about 0.5 % w/w to about 35 % w/w is formulated into capsules by blending with about 2% w/w of micro crystalline cellulose, about 0.5%> w/w of crospovidone and about 0.2%> w/w of magnesium stearate. This mixture is filled in capsules.
- composition comprising type A pentameric procyanidin flavonoid of concentration ranging from about 55 % w/w to about 99% w/w, trimers and tetramers of procyanidin flavonoid each at concentration ranging from about 0.5 % w/w to about 35 % w/w is mixed with about 961.53 ml of normal saline, about 0.0871 mg menthol and about 38.46 ml of ethyl alcohol, agitated to get a clear solution. This mixture is sterilized, filtered through about 0.04 micron filter and filled in nasal spray bottles. One shot of the nasal spray delivers about 100 ⁇ of the formulation which is equivalent to about 100 ⁇ g of instant composition.
- composition is prepared by addition of appropriate excipient(s) selected from group comprising the following: granulating agents, binding agents, lubricating agents, disintegrating agents, sweetening agents, glidants, anti-adherents, anti-static agents, surfactants, anti-oxidants, gums, coating agents, coloring agents, flavouring agents, coating agents, plasticizers, preservatives, suspending agents, emulsifying agents, additives, solvents, surfactants, viscocity enhancers, antistatic agents, plant cellulosic material and spheronization agents or any combination thereof.
- excipient(s) selected from group comprising the following: granulating agents, binding agents, lubricating agents, disintegrating agents, sweetening agents, glidants, anti-adherents, anti-static agents, surfactants, anti-oxidants, gums, coating agents, coloring agents, flavouring agents, coating agents, plasticizers, preservatives, suspending agents, emulsifying agents, additives
- the type of formulation is selected from group comprising of tablet, troches, lozenges, aqueous or oily suspensions, ointment, patch, gel, lotion, dentifrice, capsule, emulsion, creams, spray, drops, dispersible powders or granules, emulsion in hard or soft gel capsules, syrups, elixirs, nasal spray, inhalers, nebulizers, intravenous injection, intravenous solutions, intramuscular injections, intramuscular depot, subcutaneous injection, percutaneous injection, phytoceuticals, nutraceuticals and food stuffs or any combination thereof. Depending on the route of administration, different excipients/carriers are used. Those skilled in art will know to choose a suitable formulation of the instant composition for treatment, prevention and management of broncho-constrictive conditions.
- a study to assess the efficacy of the instant composition against 2 patients with perennial allergic rhinitis (PAR) and 1 patient with seasonal allergic rhinitis (SAR) is conducted.
- Patient 1 with PAR is administered about two to three shots twice daily, each shot comprising 100 ⁇ g of instant composition in nasal spray formulation. This is equivalent to 5 to 20 ⁇ g/kg of body weight of the subject, of instant composition.
- Patient 2 with PAR and Patient 3 with SAR received about 350 mg capsules of instant composition twice daily, equivalent to about 10 to 25 mg/kg of body weight of the subject per day.
- the treatment is carried out for a period of 2 months.
- the efficacy of the instant composition is analyzed on the basis of patient reported outcome taken at the beginning and end of the study period.
- the present invention demonstrates use of a pharmaceutically effective amount of a composition
- a composition comprising type-A pentameric procyanidin flavonoid of concentration ranging from about 55 % w/w to about 99% w/w, trimers and tetramers of procyanidin flavonoid each at a concentration ranging from about 0.5 % w/w to about 35 % w/w, optionally along with pharmaceutically acceptable excipient(s), for managing broncho-constrictive condition(s).
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2013103051/15A RU2532357C2 (en) | 2010-07-28 | 2011-07-27 | Method of therapy of bronchoconstrictive conditions |
CA2810163A CA2810163C (en) | 2010-07-28 | 2011-07-27 | A method of managing broncho-constrictive condition |
ES11811916T ES2900614T3 (en) | 2010-07-28 | 2011-07-27 | Method of managing a bronchoconstrictive condition |
KR1020137002339A KR101535959B1 (en) | 2010-07-28 | 2011-07-27 | A method of managing broncho-constrictive condition |
CN201180036691.5A CN103025382B (en) | 2010-07-28 | 2011-07-27 | The application of compositions in the medicine for the preparation of process bronchoconstriction disease |
EP11811916.3A EP2598206B1 (en) | 2010-07-28 | 2011-07-27 | A method of managing broncho-constrictive condition |
AU2011284357A AU2011284357B2 (en) | 2010-07-28 | 2011-07-27 | A method of managing broncho-constrictive condition |
BR112013002084-9A BR112013002084B1 (en) | 2010-07-28 | 2011-07-27 | Use of a composition comprising pentameric type a procyanidin, trimeric procyanidin and tetrameric procyanidin, for preparing medicaments for treating bronchoconstrictive condition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2145MU2010 | 2010-07-28 | ||
IN2145/MUM/2010 | 2010-07-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012014165A1 true WO2012014165A1 (en) | 2012-02-02 |
WO2012014165A8 WO2012014165A8 (en) | 2012-05-24 |
Family
ID=45529481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2011/053345 WO2012014165A1 (en) | 2010-07-28 | 2011-07-27 | A method of managing broncho-constrictive condition |
Country Status (10)
Country | Link |
---|---|
US (1) | US8563601B2 (en) |
EP (1) | EP2598206B1 (en) |
KR (1) | KR101535959B1 (en) |
CN (1) | CN103025382B (en) |
AU (1) | AU2011284357B2 (en) |
BR (1) | BR112013002084B1 (en) |
CA (1) | CA2810163C (en) |
ES (1) | ES2900614T3 (en) |
RU (1) | RU2532357C2 (en) |
WO (1) | WO2012014165A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014188325A1 (en) | 2013-05-20 | 2014-11-27 | Indus Biotech Private Limited | A method of managing hepatic fibrosis, hepatitis c virus and associated condition |
EP2829277A1 (en) | 2013-07-26 | 2015-01-28 | Natac Biotech, S.L. | Use of a-type proanthocyanidins in treating a mineralocorticoid receptor related disease |
CN104582699A (en) * | 2012-08-07 | 2015-04-29 | 英德斯生物技术私营有限公司 | A method of managing diabetic foot ulcers, pressure ulcers, venous leg ulcers and associated complication |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2803549T3 (en) * | 2013-09-23 | 2021-01-27 | Nestle Sa | Cocoa polyphenols for use in the treatment or prevention of eosinophilic esophagitis |
WO2022123513A1 (en) * | 2020-12-10 | 2022-06-16 | Indus Biotech Private Limited | Composition and method for managing coronavirus infection |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001045726A2 (en) * | 1999-12-21 | 2001-06-28 | Mars, Incorporated | The use of procyanidins in the modulation of cytokine gene expression and protein secretion |
WO2007053641A2 (en) | 2005-11-01 | 2007-05-10 | Mars, Incorporated | A-type procyanidins and inflammation |
WO2010075611A1 (en) * | 2009-01-05 | 2010-07-08 | Bio - Enhancements Pty Ltd | Composition comprising proanthocyanidin, proteolytic enzyme and aloe vera/agave species substance |
WO2011018793A1 (en) * | 2009-08-11 | 2011-02-17 | Indus Biotech Private Limited | A novel standardized composition, method of manufacture and use in the resolution of rna virus infection |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100111927A1 (en) * | 2002-08-23 | 2010-05-06 | Sunyoung Kim | Compositions Comprising Actinidia and Methods of Use Thereof |
WO2005030200A1 (en) * | 2003-09-26 | 2005-04-07 | Kirin Beer Kabushiki Kaisha | Remedy for autoimmune diseases |
JP2006096693A (en) * | 2004-09-29 | 2006-04-13 | Tohoku Univ | Antiallergic agent |
CN1861072A (en) * | 2005-05-12 | 2006-11-15 | 牛蓉 | Use of malic polyphenols for preparing medicines to treat bronchitis or asthma |
WO2007091151A2 (en) * | 2006-02-06 | 2007-08-16 | Indus Biotech Private Limited | A synergistic pharmaceutical and/or neutraceutical flavanoid composition for management of diabetes mellitus |
-
2011
- 2011-07-27 AU AU2011284357A patent/AU2011284357B2/en active Active
- 2011-07-27 WO PCT/IB2011/053345 patent/WO2012014165A1/en active Application Filing
- 2011-07-27 ES ES11811916T patent/ES2900614T3/en active Active
- 2011-07-27 EP EP11811916.3A patent/EP2598206B1/en active Active
- 2011-07-27 RU RU2013103051/15A patent/RU2532357C2/en active
- 2011-07-27 US US13/192,306 patent/US8563601B2/en active Active
- 2011-07-27 CA CA2810163A patent/CA2810163C/en active Active
- 2011-07-27 KR KR1020137002339A patent/KR101535959B1/en active IP Right Grant
- 2011-07-27 BR BR112013002084-9A patent/BR112013002084B1/en active IP Right Grant
- 2011-07-27 CN CN201180036691.5A patent/CN103025382B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001045726A2 (en) * | 1999-12-21 | 2001-06-28 | Mars, Incorporated | The use of procyanidins in the modulation of cytokine gene expression and protein secretion |
WO2007053641A2 (en) | 2005-11-01 | 2007-05-10 | Mars, Incorporated | A-type procyanidins and inflammation |
WO2010075611A1 (en) * | 2009-01-05 | 2010-07-08 | Bio - Enhancements Pty Ltd | Composition comprising proanthocyanidin, proteolytic enzyme and aloe vera/agave species substance |
WO2011018793A1 (en) * | 2009-08-11 | 2011-02-17 | Indus Biotech Private Limited | A novel standardized composition, method of manufacture and use in the resolution of rna virus infection |
US20110039923A1 (en) | 2009-08-11 | 2011-02-17 | Indus Biotech Private Limited | Novel standardized composition, method of manufacture and use in the resolution of rna virus infection |
Non-Patent Citations (2)
Title |
---|
ROHDEWALD P.: "A Review of the French Maritime Pine Park Extract (Pycnogenol), a Herbal Medication With a Diverse Clinical Pharmacology", INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 40, no. 4, 2002, pages 158 - 168, XP009027806 * |
See also references of EP2598206A4 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104582699A (en) * | 2012-08-07 | 2015-04-29 | 英德斯生物技术私营有限公司 | A method of managing diabetic foot ulcers, pressure ulcers, venous leg ulcers and associated complication |
EP2882434A4 (en) * | 2012-08-07 | 2015-06-17 | Indus Biotech Private Ltd | A method of managing diabetic foot ulcers, pressure ulcers, venous leg ulcers and associated complication |
CN104582699B (en) * | 2012-08-07 | 2019-10-22 | 英德斯生物技术私营有限公司 | Control diabetic foot ulcer, pressure ulcer, venous leg ulcers and related complication method |
WO2014188325A1 (en) | 2013-05-20 | 2014-11-27 | Indus Biotech Private Limited | A method of managing hepatic fibrosis, hepatitis c virus and associated condition |
CN105451733A (en) * | 2013-05-20 | 2016-03-30 | 英德斯生物技术私营有限公司 | A method of managing hepatic fibrosis, hepatitis c virus and associated condition |
EP2999468A4 (en) * | 2013-05-20 | 2017-01-18 | Indus Biotech Private Limited | A method of managing hepatic fibrosis, hepatitis c virus and associated condition |
EP2829277A1 (en) | 2013-07-26 | 2015-01-28 | Natac Biotech, S.L. | Use of a-type proanthocyanidins in treating a mineralocorticoid receptor related disease |
Also Published As
Publication number | Publication date |
---|---|
EP2598206A1 (en) | 2013-06-05 |
ES2900614T3 (en) | 2022-03-17 |
AU2011284357A1 (en) | 2013-02-07 |
CA2810163C (en) | 2018-05-01 |
CN103025382B (en) | 2016-04-20 |
KR20130050957A (en) | 2013-05-16 |
EP2598206B1 (en) | 2021-09-22 |
US8563601B2 (en) | 2013-10-22 |
EP2598206A4 (en) | 2014-04-30 |
RU2532357C2 (en) | 2014-11-10 |
RU2013103051A (en) | 2014-09-10 |
BR112013002084B1 (en) | 2022-02-01 |
US20120190736A1 (en) | 2012-07-26 |
CA2810163A1 (en) | 2012-02-02 |
CN103025382A (en) | 2013-04-03 |
AU2011284357B2 (en) | 2013-09-26 |
KR101535959B1 (en) | 2015-07-10 |
BR112013002084A2 (en) | 2020-09-01 |
WO2012014165A8 (en) | 2012-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2810163C (en) | A method of managing broncho-constrictive condition | |
US8835415B2 (en) | Standardized composition, method of manufacture and use in the resolution of RNA virus infection | |
JP2019530751A (en) | Cannabinoid-containing complex mixture for treating neurodegenerative diseases | |
US20050079136A1 (en) | Aerosol formulations of delta tetrahydrocannabinol | |
US20200054595A1 (en) | EGCG-Palmitate Compositions and Methods of Use Thereof | |
US20230158038A1 (en) | Treating influenza using substituted polycyclic pyridone derivatives and prodrugs thereof in a subject having influenza and a complication risk factor | |
US11504350B2 (en) | Cannabinoid compositions and methods of use thereof | |
US20210196673A1 (en) | Compositions and methods for treating and preventing respiratory viral infections using green tree extract | |
WO2009099405A2 (en) | Antibacterial compositions and methods of treatment | |
TWI421072B (en) | A method of managing broncho-constrictive condition | |
US8124654B2 (en) | Derivatives of hypoestoxide and related compounds | |
WO2022123513A1 (en) | Composition and method for managing coronavirus infection | |
US20220168265A1 (en) | Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight | |
CN115811969A (en) | Compositions and methods for preventing and treating fibrotic and inflammatory disorders | |
Kumar et al. | Quercetin Bioflavonoids Derived from Phytomedicinal Compounds for Targeted Drug Delivery and Their Antioxidant Properties | |
TWI389700B (en) | A novel standardized composition, method of manufacture and use in the resolution of rna virus infection | |
KR20040097820A (en) | Composition for prevention and treatment of asthma comprising α-lipoic acid as an effective component |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180036691.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11811916 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2810163 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 20137002339 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011811916 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2011284357 Country of ref document: AU Date of ref document: 20110727 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2013103051 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013002084 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013002084 Country of ref document: BR Kind code of ref document: A2 Effective date: 20130128 |